A multidisciplinary team of McCarter lawyers advised Chondrial Therapeutics, Inc., on its definitive merger agreement with Zafgen, Inc. (Nasdaq: ZFGN) under which Chondrial will acquire Zafgen in a reverse merger wherein the stockholders of Chondrial will become the majority owners of Zafgen’s outstanding common stock. The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under the name Larimar Therapeutics, Inc.
Chondrial Therapeutics is a clinical-stage biotechnology company focused on the treatment of complex rare diseases. Zafgen is a biopharmaceutical company that has leveraged its proprietary biology platform to pioneer the study of common and rare metabolic disorders.
McCarter’s team was led by Philip Amoa and Peter Campitiello, and included Dan Kelly, Pat Harrity, Debra Levin, Jill Mello, Keith Toms, Joel Horowitz, Sheri Pastor, and Pam Moore.
Additional details are available in the press release.